Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Synovian
- Development stage
- Phase 3
- Lead developer
- LG Chem
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Intra-articular Injection
01
Overview
Synovian is an intra-articular injection composed of 1,4-butanediol diglycidyl ether (BDDE) cross-linked hyaluronic acid. It is indicated for the treatment of mild to moderate knee osteoarthritis, functioning as a viscosupplement to alleviate pain and enhance joint mobility. Post-marketing surveillance studies in South Korea have confirmed its safety and effectiveness in real-world clinical settings, demonstrating significant reductions in pain scores. Synovian is also frequently utilized as an active comparator in clinical trials evaluating new hexamethylenediamine (HMDA) cross-linked hyaluronate injections (such as SP5M001 and SP5M002) and divinyl sulfone (DVS) cross-linked hyaluronate (YYD302) for knee osteoarthritis.
- Brand names
- Synovian
- Other names
- BDDE cross-linked sodium hyaluronate gelcross-linked sodium hyaluronate gel
Beyond the preview
Go deeper on Synovian.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synovian.